Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab for COVID-19 Vasculopathy
NCT04435184Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Crizanlizumab Arm with Placebo Arm (2 arms). Primary endpoint: Soluble P-selectin at 3 days. Started Jul 2020; status: completed.
02
Drugs
crizanlizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04435184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435184.